| Literature DB >> 24643868 |
Devasthanam Sundara Rao KrupaShankar1, Vijay Kumar Somani, Malvika Kohli, Jaishree Sharad, Anil Ganjoo, Sanjiv Kandhari, Venkat Ram Mysore, Sanjeev Aurangabadkar, Subrata Malakar, Maya Vedamurthy, Ganesh Kadhe, Salman Motlekar, Pashmina Ahirrao.
Abstract
BACKGROUND: Melasma is one of the most common pigment disorders seen by a dermatologist and often occurs among women with darker complexion (skin type IV-VI). AIMS: The present study aimed to investigate the epidemiology of melasma in the Indian population and to focus on the regional variability in the demographics, clinical manifestations and factors that precipitate this condition.Entities:
Year: 2014 PMID: 24643868 PMCID: PMC4065278 DOI: 10.1007/s13555-014-0046-1
Source DB: PubMed Journal: Dermatol Ther (Heidelb)
Demographic details
| Location | East | West | North | South | Overall |
|
|---|---|---|---|---|---|---|
| Sample size ( | 44 | 82 | 78 | 127 | 331 | |
| Age (years, mean ± SD) | 34.3 ± 8.9 | 38.6 ± 7.7 | 40.2 ± 9.2 | 35.4 ± 9.9 | 37.2 ± 9.3 | 0.0003* |
| Sex (M/F) | (10/34) | (13/69) | (13/65) | (29/98) | (65/266) | 0.5604‡ |
| Marital status (married/single) | (23/21) | (69/13) | (68/10) | (97/30) | (257/74) | <0.001‡ |
| Family history (Yes; %) | 8 (18.18) | 23 (28.04) | 30 (38.46) | 42 (33) | 103 (31.11) | 0.1207‡ |
n number of patients, SD standard deviation
‡Chi-square test
* One-way ANOVA
Baseline characteristics of the patients
| Explanatory variable | Parameter | Regions ( | Overall ( | |||
|---|---|---|---|---|---|---|
| North ( | East ( | West ( | South ( | |||
| Age at onset (years) | <20 | 3 (4%) | 3 (7%) | 8 (10%) | 6 (4%) | 20 (6%) |
| 20–29 | 13 (17%) | 20 (45%) | 24 (29%) | 38 (30%) | 95 (29%) | |
| 30–39 | 31 (40%) | 16 (36%) | 35 (43%) | 54 (42%) | 136 (41%) | |
| 40–49 | 24 (31%) | 5 (11%) | 14 (17%) | 24 (19%) | 67 (20%) | |
| >50 | 7 (9%) | 0 | 1 (1%) | 5 (4%) | 13 (4%) | |
| Disease chronicity (years) | <1 | 12 (15%) | 7 (16%) | 15 (18%) | 2 (2%) | 36 (11%) |
| 1–2 | 19 (24%) | 9 (20%) | 19 (23%) | 55 (43%) | 102 (31%) | |
| 2–3 | 15 (19%) | 5 (11%) | 13 (16%) | 18 (14%) | 51 (15%) | |
| >3 | 32 (41%) | 23 (52%) | 35 (43%) | 52 (42%) | 142 (43%) | |
| Melasma pattern | Centrofacial | 43 (55%) | 23 (52%) | 32 (39%) | 42 (33%) | 140 (42%) |
| Malar | 17 (22%) | 21 (48%) | 41 (50%) | 51 (40%) | 130 (39%) | |
| Mandibular | 4 (5%) | 0 | 0 | 0 | 4 (1%) | |
| Centrofacial and malar | 14 (18%) | 0 | 9 (11%) | 24 (19%) | 47 (14%) | |
| Centrofacial and mandibular | 0 | 0 | 0 | 1 (1%) | 1 | |
| Malar and mandibular | 0 | 0 | 0 | 1 (1%) | 1 | |
| Centrofacial, malar and mandibular | 0 | 0 | 0 | 8 (6%) | 8 (2%) | |
| Distribution | Cheeks | 74 (95%) | 44 (100%) | 75 (91%) | 117 (92%) | 310 (94%) |
| Nose | 36 (46%) | 18 (41%) | 42 (51%) | 59 (46%) | 115 (35%) | |
| Forehead | 21 (27%) | 15 (34%) | 19 (23%) | 31 (24%) | 86 (26%) | |
| Upper lip | 3 (4%) | 7 (16%) | 8 (10%) | 14 (11%) | 32 (10%) | |
| Chin | 2 (2%) | 1 (2%) | 6 (7%) | 8 (6%) | 17 (5%) | |
| Mandible | 4 (5%) | 0 | 0 | 7 (5%) | 11(3%) | |
| Etiology sunscreen usage cosmetic usage | Duration of sun exposure (h) | 29.84 ± 16.9 | 32.1 ± 15.4 | 32.7 ± 20.1 | 42.9 ± 33.8 | 35.9 ± 25.7 |
| Yes | 54 (69%) | 11 (25%) | 36 (44%) | 16 (13%) | 117 (35%) | |
| Yes | 16 (20%) | 22 (50%) | 37 (45%) | 16 (20%) | 116 (35%) | |
| Pregnancy | Single | 4 (5%) | 9 (20%) | 21 (26%) | 33 (26%) | 67 (20%) |
| Multiple | 45 (58%) | 11 (25%) | 36 (44%) | 44 (35%) | 136 (41%) | |
| No | 16 (21%) | 14 (32%) | 12 (15%) | 21 (17%) | 63 (19%) | |
| Menopause status | Yes | 10 (13%) | 0 | 8 (10%) | 19 (15%) | 37 (11%) |
| Oral contraceptive usage | Yes | 8 (10%) | 10 (23%) | 2 (2%) | 3 (2%) | 23 (7%) |
| Socioeconomic class | Lower Middle | 0 | 2 (5%) | 12 (15%) | 29 (23%) | 43 (13%) |
| Upper Lower | 0 | 2 (5%) | 8 (10%) | 5 (4%) | 17 (5%) | |
| Upper Middle | 72 (92%) | 26 (59%) | 39 (48%) | 80 (63%) | 217 (66%) | |
| Upper | 6 (8%) | 14 (32%) | 23 (28%) | 11 (9%) | 54 (16%) | |
| Quality of life [IQR] | 3 [1–5] | 4 [4–5] | 6 [3.25–7] | 4 [2–5] | 4 [2–5] | |
| Treatment used | Triple combination | 20 (26%) | 19 (43%) | 52 (63%) | 24 (19%) | 115 (35%) |
| Monotherapy | 17 (22%) | 6 (14%) | 1 (1%) | 0 | 24 (7%) | |
| Combination therapy | 0 | 0 | 0 | 0 | 0 | |
| HQ–AHA combination | 3 (4%) | 0 | 2 (2%) | 0 | 5 (2%) | |
| Superficial chemical peel | 0 | 12 (27%) | 40 (49%) | 1 (1%) | 53 (5%) | |
| Vitamin C | 0 | 1 (2%) | 13 (16%) | 1 (1%) | 15 (5%) | |
| No treatment | 38 (49%) | 17 (39%) | 12 (15%) | 102 (80%) | 169 (51%) | |
IQR inter-quartile range, HQ–AHA hydroquinone–aminohydroxy acids
Fig. 1Effect of various explanatory variables on prevalence of melasma